TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Response rate (including complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Ulcer Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain frequency
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time of appearance of plasma triglyceride peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of seizure activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3-year failure free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Discontinued From Study Therapy Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pad Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Stress Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Patient Safety-Related Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient Safety Behavior
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Proportional Ratios of study subjects with mRS 0-2 scores at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence rate of cerebral hemorrhagic transformation within 48 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Inter-day reliability in post-prandial nutrient oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Experiencing Drug-related Adverse Experiences Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Drug-related Serious Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in healthy weight habits
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Defervescence (without hypothermia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Venous thromboembolism occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximal Fall in Forced Expiratory Volume in One-second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mitral valve E/e' ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in insulin-like growth factor-1 (IGF-1) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients receiving RBC transfusion perioperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: prevalence of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measure of impulse control (rMIDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of IKZF-1 deletion mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of BCR-ABL translocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SUV max in GA-68 DOTATOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Gingival Indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Renal function loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Differential Cost Result Ratio (DCRR)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients following a diet for rheumatic disease
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: High frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of skin self-examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance of skin self-examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety / Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: No liver-related death or LTx
Endpoint domain: Mortality/survival
Primary endpoint: Amelioration of PBC histological stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Field of regard-response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Field of regard-success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Field of regard-head movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HeartQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants aspirating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Induced Respiratory Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chemotherapy induced peripheral neuropathic pain (CIPN) score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in movement time (seconds) for reaching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in accuracy of reaching (root mean square error)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in efficiency of reaching (number of velocity peaks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining pulp vitality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum plasma concentration (Tmax) of multiple oral doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment protocol adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Grade II-IV Acute Graft-versus-Host Disease (GVHD) Score at 100 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FSI-10 score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Muscular sympathetic nervous activity (MSNA) in bursts / 100 heart beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adjusted Mean Change in Wake Time During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC infinity for CYP2C9 (tolbutamide) substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC infinity for CYP2D6 (metoprolol) substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC infinity for CYP2E1 (chlorzoxazone) substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC infinity for OAT1/OAT3 (furosemide) substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Glucose Insulin Sensitivity Index (OGIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early phase insulin response during OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve for incretin hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Analgesic efficacy of nonopioid analgesic mixture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venipuncture success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obtention of 3D ultrasound images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in absolute functional connectivity values in migraine group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in absolute functional connectivity values in Responders vs. Non-Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of patients meeting the exercise goal
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in percentage of patients meeting the body mass index (BMI) goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of patients meeting the posttraumatic growth inventory (PTGI) goal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fibromyalgia Impact Questionnaire (FIQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver Overload Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Carers Assessment Satisfaction Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Carers Assessment Difficulties Index
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of days spent hazardously drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotator cuff muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of seroconversion (anti-rota serum IgA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Connectivity of resting state neural networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Follow-up at 60 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rates of excretion of LBH589 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of CT-322
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose for CT-322
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Best response according to iRECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biochemically-validated past 7-day point prevalence tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Alcohol Drinks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-Menstrual Pelvic Pain Responder Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Idalopirdine plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal to Noise Ratio (SNR) Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIP occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of deliveries with ventilatory assistance during delayed cord clamping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death due to stroke or ischemic heart disease
Endpoint domain: Mortality/survival
Primary endpoint: Sexual Encounter Profile Question 2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in motion discrimination thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra Class Coefficient of Correlation (ICC) of the Task Activated BOLD fMRI: Face Matching Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra Class Coefficient of Correlation (ICC) of the Task Activated BOLD fMRI: Monetary Incentive Delay Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra Class Coefficient of Correlation (ICC) of the Task Activated BOLD fMRI: 2 vs 0 Back Working Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Excretion of Oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in muscle function (hand grip)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle function (gait test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Aborted cardiac arrest events
Endpoint domain: Mortality/survival
Primary endpoint: improvement in KOOS pain subscales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Any Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinuing the Study Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative hospitalization time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in American Shoulder and Elbow Score (ASES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Range of Motion (ROM) Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of coronary and valvular calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in non-specific chronic low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Motility (Anorectal Sensation and Strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of complications necessitating PICC removal
Endpoint domain: Adverse events/effects
Primary endpoint: Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of GSK933776 after single dose SQ or IM administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of GSK933776 after repeat dose SQ administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in miRNAs content of circulating tumor exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in protein content of circulating tumor exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: VASP test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Cardiac MicroRNA Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delayed adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: HIV/STI testing uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PrEP uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Digit Span Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trial Making Test (TMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Free testosterone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Nursing Care Index (NCI)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Patient Satisfaction with Nursing Care Quality (PSNCQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of Microvascular Dysfunction (MVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Signs and Symptoms of Blepharitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of clinically atypical parkinsonism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximal Oxygen consumption (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat oxidation rates (FORs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in depression summary scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety summary scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Spiritual well-being summary scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of donor site area healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects free from specified adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of Rutherford Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Subjects with patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants with good compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects With Greater Than Grade 3 or 4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: iAUC-0.25-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative difference in pharmacokinetics (PK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical strength and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial infarction or coronary revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vascular and Systemic Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in expression levels of plasma miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement as measured by EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life impairment as measured by EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline of the EuroQoL Five Dimensions Questionnaire (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Average Usability Score Using the Software Usability Scoring System
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in quality of Life - FACT-ES - B5 - H18
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cytokine Interleukin-6 (IL-6) mRNA Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uncoupling Protein 1 (UCP1) mRNA Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Signal Transducer and Activator of Transcription 3 (STAT3) Band Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Serum Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Unacylated Ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ghrelin area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intensity of immunofluorescence staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of underlying susceptibility trait(s) identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypnotic substance identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alveolar macrophage phagocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intrapulmonary oxidative stress indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive reaction time of urease test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolactin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the Lower Extremity Functional Scale (LEFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fluid Cognition (Composite)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Urinary, fecal, and respiratory excretion of 14C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PK parameters of total radioactivity in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic profile of FTD and TPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of Latency and duration of the cutaneous silent period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cell DNA Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes